Form 4: Spero Therapeutics COO Sells Shares for Tax Obligations

Spero Therapeutics' Chief Operating Officer, Timothy Keutzer, sold 18,652 shares of common stock to cover tax withholding obligations related to RSU vesting.

Summary

• Timothy Keutzer, Chief Operating Officer of Spero Therapeutics, Inc., reported a transaction involving the company's common stock.
• On February 6, 2026, Keutzer disposed of 18,652 shares of Spero Therapeutics common stock.
• The shares were sold at a price of $2.36 per share.
• This transaction was a "sell to cover" to satisfy tax withholding obligations associated with the vesting of Restricted Stock Units (RSUs) and was not a discretionary trade.
• Following this transaction, Keutzer beneficially owns 742,506 shares of common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as it is a routine 'sell to cover' transaction for tax purposes related to RSU vesting, not a discretionary sale indicating a change in executive sentiment.

Positives

• The transaction indicates the vesting of Restricted Stock Units (RSUs), suggesting that the executive is receiving compensation in the form of company equity.
• The "sell to cover" mechanism is a standard, non-discretionary process for executives to manage tax liabilities on vested equity, which is a positive for transparency and compliance.

Negatives

• The transaction results in a reduction of the Chief Operating Officer's direct beneficial ownership by 18,652 shares.

Risks

• No specific risks are mentioned in this Form 4 filing beyond the inherent risks associated with equity compensation and tax obligations.

Future Outlook

No forward-looking statements or guidance are provided in this Form 4 filing, as it pertains solely to a past insider transaction.

Industry Context

StockSavvy.ai notes that 'sell to cover' transactions are a common and routine occurrence in the biotechnology and pharmaceutical industries, where executive compensation often includes Restricted Stock Units (RSUs). These sales are typically non-discretionary and are executed to meet tax obligations upon RSU vesting, rather than signaling a change in management's outlook on the company's prospects. This transaction for Spero Therapeutics' COO aligns with standard practices for equity compensation in the sector.

Comparison to Industry Standards

• StockSavvy.ai observes that the 'sell to cover' transaction by Spero Therapeutics' COO is consistent with common practices across publicly traded companies, particularly in high-growth sectors like biotechnology.
• For instance, executives at companies such as Moderna (MRNA) or BioNTech (BNTX) frequently engage in similar non-discretionary sales to cover tax liabilities upon the vesting of their equity awards.
• This type of transaction is a standard mechanism for managing the tax implications of RSU vesting and does not typically indicate a unique or unusual event for SPRO when compared to its peers.

Related Party Transactions

• The transaction itself is a related party transaction (insider selling shares to cover taxes on RSU vesting), but no other specific related party dealings are disclosed beyond the executive's compensation structure.

Stakeholder Impact

• Shareholders: A minor reduction in insider ownership, but generally viewed as a routine administrative event with minimal impact on overall shareholder sentiment or company valuation.
• Employees: No direct impact on employees, but it reflects the standard equity compensation practices for executives.

Key Dates

Recommendation

This Form 4 filing details a routine 'sell to cover' transaction by an executive to satisfy tax obligations on vested Restricted Stock Units. It is explicitly stated as non-discretionary and does not reflect a change in the executive's investment thesis or outlook on the company. As such, it provides no new fundamental information that would warrant a change in investment recommendation. A 'hold' recommendation is appropriate as this administrative event does not alter the underlying investment case for Spero Therapeutics.

Keywords

Spero Therapeutics, SPRO, Form 4, insider trading, beneficial ownership, RSU vesting, sell to cover, executive compensation, Timothy Keutzer, Chief Operating Officer